CASE REPORT

Clinical Efficacy of Vorinostat in a Patient with Leiomyosarcoma

Jin Lee and Colin McGuire

University of Pittsburgh Medical Center, Arnold Palmer Pavilion at Mountain View Medical Park, Greensburg, Pennsylvania, USA. Corresponding author email: leejs@upmc.edu

Abstract: Leiomyosarcoma is a heterogeneous tumor group, representing <1% of all new cancers diagnosed in United States. Treatment choice is based upon site, grade, and extent of disease. However, prognosis for metastatic or unresectable sarcoma is very poor with reported median survival of 12 months. Response to chemotherapy has been approximately 8% to 39% based upon the chemotherapeutic agent and whether used alone or in combination. Vorinostat is an orally active, potent, and competitive inhibitor of histone deacetylases approved for cutaneous T-cell lymphoma. There are limited preclinical data illustrating the activity of histone deacetylase inhibitors in sarcoma. Here is a case of a lady with leiomyosarcoma who has progressed through multiple chemotherapeutic agent who has achieved a partial response to vorinostat treatment.

Keywords: histone deacetylase inhibitor, vorinostat, leiomyosarcoma, lung metastases, soft tissue sarcoma
Introduction

Soft tissue sarcomas are a rare heterogeneous tumor group, representing <1% (approximately 10,000 cases) of all new cancers diagnosed yearly in the United States.¹ Over 50 subtypes of malignant soft tissue sarcomas have been described in adults,² leiomyosarcomas are one of the most common.² Leiomyosarcomas are tumors of distinct smooth muscle type cells and occur intramuscularly and subcutaneously.²

Treatment choices for leiomyosarcomas are influenced by the site, grade, and extent of disease, and may include surgery, chemotherapy, and radiotherapy. Surgical resection offers the best chance of cure and is sometimes coupled with radiotherapy.³ However, metastatic or unresectable sarcoma is rarely curable with reported median survival time of approximately 12 months and 5-year survival rates of 10%–15%.⁴ Chemotherapy may have substantial benefits for patients with metastatic or unresectable sarcoma and of the agents that have been utilized to treat soft tissue sarcomas, the most common are doxorubicin, ifosfamide, and, more recently, gemcitabine, both alone and in combination with taxanes.⁵ However, repeated and/or prolonged use of these agents is prohibited by their limited efficacy and/or associated toxicity. Response rates of approximately 20%, 39%, 8%, and 16% have been reported for doxorubicin, ifosfamide, gemcitabine alone, and in combination with docetaxel, respectively.⁵⁻⁷ In addition, radiotherapy has been combined with chemotherapy as well as being used alone to treat unresectable sarcoma.³

Vorinostat (Zolinza®, Merck Sharp & Dohme, a subsidiary of Merck & Co., Inc.), an orally active, potent, and competitive inhibitor of histone deacetylases (HDAC),⁸ was approved by the US Food and Drug Administration (FDA) in October 2006 for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent, or recurrent disease on or following two systemic therapies.⁹ Vorinostat has demonstrated promising efficacy in Phase I trials in a wide range of solid malignancies.¹⁰ Here we report on a female patient with leiomyosarcoma with an apparent response to vorinostat treatment after multiple previous chemotherapy treatments.

Case Report

In September 2005, a 43-year-old, asymptomatic female presented with an increasing mass (4 × 3 cm) in her left thigh which involved the subcutaneous tissue down to the muscular fascia and adductor canal. An immunohistochemical examination on the excised tumor confirmed it was positive for smooth muscle actin, heavy chain myosin, vimentin, and S100 protein. Hence, the tumor was identified as a sarcoma consistent with leiomyosarcoma. Additional biopsies performed during the patient’s therapy confirmed this initial diagnosis. Once leiomyosarcoma was diagnosed the patient underwent computed tomography (CT) of the chest, abdomen, and pelvis which revealed multiple lung nodules and a tumor (2.2 cm rounded structure) in the myometrium of the left side of the uterine wall, which effaced the uterine cavity. The uterine tumor was c-kit estrogen/progesterone receptor negative; however, its origin was inconclusive. The patient initially (October 2005) received combination chemotherapy of doxorubicin (50 mg/m²), ifosfamide (2000 mg/m²), and mesna (2000 mg/m²) every 21 days for a total of 6 cycles (finishing January 2006). A partial response based upon the CT findings was achieved.

Regrettfully, disease recurred 6 months later and the above treatment regimen was resumed for 4 cycles (finishing October 2006). Once more, the patient responded well until disease recurred again approximately 4 months later; when combination chemotherapy with gemcitabine (800 mg/m²) and docetaxel (75 mg/m²) was commenced. However, the patient developed Grade 4 mucositis and pancytopenia during the first cycle necessitating hospital admission and treatment was subsequently reduced to single-agent gemcitabine (1000 mg/m², once weekly for 2 weeks followed by 1 week rest). The patient responded well and received 5 single-agent gemcitabine cycles in total (finishing April 2007).

Disease again recurred approximately 4 months later and treatment with single-agent gemcitabine was resumed; however, CT showed disease progression after 2 cycles and combination chemotherapy of doxorubicin, ifosfamide, and mesna was recommenced once more. However, after 2 cycles of this combination, no response was observed. Confronted with a lack of established therapy options in this
setting, the patient was offered the opportunity to either enter a clinical trial or receive vorinostat. Vorinostat was recommended based on Phase I results in patients with refractory solid tumors. Vorinostat (400 mg/day) was started approximately 2 years after diagnosis (November 2007), stable disease (SD) was observed after 6 weeks and maintained. Furthermore, some shrinkage was observed at 3 months in both her liver and lung metastases. The patient experienced mild nausea initially which subsided after a couple of months. Her complete blood count and metabolic values remained within normal limits whilst receiving vorinostat.

The patient remained on vorinostat for 18 months (finishing April 2009) when she developed progressive disease and subsequently received single-agent ifosfamide, and mesna which failed to produce a response. The patient then received single-agent dacarbazine followed by single-agent paclitaxel, both of which failed to produce a response. After evaluating all of her treatment options, the patient selected doxorubicin therapy despite the cardiac risk; however, after two cycles of weekly chemotherapy, with no response, treatment was stopped. The patient then chose to enter a hospice and died approximately 3.5 years after diagnosis (July 2009).

**Discussion**

In common with many patients with recurrent relapsing leiomyosarcoma, our patient had exhausted all treatment options for effective chemotherapy; including first- and second-line combination chemotherapy of doxorubicin, ifosfamide, and mesna which followed by combination gemcitabine and docetaxel which was stopped due to Grade 4 adverse events (AEs) and replaced with single-agent gemcitabine, followed by doxorubicin, ifosfamide, and mesna upon relapse. The best and longest duration of response, overall SD for over 1.5 years, was achieved with vorinostat (400 mg/day), with initial mild nausea which resolved, and with some metastases shrinkage. Our case is the first to report an apparent effect of vorinostat in the treatment of leiomyosarcoma. Vorinostat has been approved for the treatment of CTCL and has shown efficacy in a number of additional hematologic malignancies and promising efficacy in other solid tumor types such as breast cancer, lung cancer, and mesothelioma. In a Phase IIb study in patients with persistent, progressive, or recurrent CTCL the objective response rate with vorinostat monotherapy was 29.7%, and 32.3% of patients (with baseline pruritus scores ≥3) had pruritus relief. The most common drug-related AEs were diarrhea, fatigue, nausea, and anorexia, most of which were ≤grade 2; AEs of Grade 3 and above included fatigue, pulmonary embolism, thrombocytopenia, and nausea. In an extension study, patients who had completed ≥6 months of treatment in the Phase IIb study were eligible to continue vorinostat treatment, until disease progression or unacceptable toxicity. Fifteen of the initial 74 patients entered the extension study and six of these patients continued on vorinostat therapy for more than 2 years. The most common drug-related AEs in the continuation study were diarrhea, nausea, fatigue, and alopecia and the incidence of Grade 3–4 AEs was low. To date, five patients have discontinued vorinostat and one patient continues to respond after 1445 days (4.0 years). Both the clinical trials and post-trial clinical experience have confirmed the efficacy and tolerability of vorinostat. Compared with conventional cytotoxic agents, vorinostat has a favorable tolerability profile with both short- and long-term use. Thus unlike the cytotoxics, vorinostat has the potential for extended use.

A variety of genetic changes have been observed in leiomyosarcoma, often including changes in TP53 and MDM2 expression, overexpression of cyclin-dependent kinase inhibitor 2A (CDKN2A; p16), and a loss of gamma-smooth muscle isoactin expression. These findings support a preclinical rationale for the potential clinical utility of targeted agents in the management of leiomyosarcoma. Vorinostat is a small molecule inhibitor of Class I and II HDAC enzymes, which catalyze the removal of acetyl groups from histone proteins on nucleosomes, with histone acetyltransferases (HATs) facilitating the acetylation of these proteins. Histone hypoacetylation results in closed chromatin structures and repression of important tumor suppressor genes. Consequently, HAT inactivation has been associated with tumorigenesis and aberrant HDAC activity has been related to the development and maintenance of human tumors, including CTCL. In addition, HDACs have many other non-histone proteins as substrates, such
as transcription factors (p53), α-tubulin, heat shock protein 90 (Hsp90) and various signaling proteins.28

There are limited preclinical data reporting the activity of HDAC inhibitors in sarcoma.31–39 Ecke and co-workers observed that combined 5-aza-2′-deoxycytidine (a DNA methylation inhibitor) and valproic acid (a HDAC inhibitor) efficiently prevented medulloblastoma and rhabdomyosarcoma formation in patched mutant mice.32 Nguyen and co-workers observed that the Hsp90 inhibitor 17-AAG and the HDAC inhibitor MS-275 had synergistic, antiproliferative, and proapoptotic effects on synovial sarcoma in vitro.31 Additionally, the HDAC inhibitors MS-275, trichostatin-A, phenylbutyrate, LAQ824, and depsipeptide, enhanced the antineoplastic action of 5-aza-2′-deoxycytidine on Ewings sarcoma cells.33 While Sakimura and colleagues noted that depsipeptide inhibited chondrosarcoma cell growth, up-regulated the expression of aggregan and alpha2 chain of type XI collagen (COL11A2) mRNA, and induced differentiation to a hypertrophic cell phenotype.37 Two studies with vorinostat have reported growth inhibition of chondrosarcoma cells, significant inhibition of tumor growth in a xenograft model, and death of endometrial stromal sarcoma cells.34,36 This case, which demonstrates promising activity of HDAC inhibitors in sarcoma, represents one of the first clinical applications of an HDAC inhibitor in soft tissue sarcoma. However, this is only one case report and more studies are needed to confirm the activity and efficacy of vorinostat in leiomyosarcoma.

Acknowledgment
The author would like to thank Dr Fiona Boswell, from Complete Medical Communications, who provided medical writing support funded by Merck Sharp & Dohme, a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA.

Disclosure
Author(s) have provided signed confirmations to the publisher of their compliance with all applicable legal and ethical obligations in respect to declaration of conflicts of interest, funding, authorship and contributorship, and compliance with ethical requirements in respect to treatment of human and animal test subjects. If this article contains identifiable human subject(s) author(s) were required to supply signed patient consent prior to publication. Author(s) have confirmed that the published article is unique and not under consideration nor published by any other publication and that they have consent to reproduce any copyrighted material. The peer reviewers declared no conflicts of interest.

References
1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96.
2. van Vliet M, Kliffen M, Krestin GP, et al. Soft tissue sarcomas at a glance: clinical, histological, and MR imaging features of malignant extremity soft tissue tumors. Eur Radiol 2009;19:1499–511.
3. McMillian Cancer support group: treating soft tissue sarcomas, 09 update. http://www.maccmillian.org.uk/Cancerinformation/Cancertypes/Softtissuesarcomas/Treatingsofttissuesarcomas/Treatingsofttissuesarcomas.aspx Accessed November 19, 2009.
4. Brennan MF, Singer S, Maki RG, et al. Sarcomas of the soft tissue and bone, in DeVita VT Jr, Hellman S, Rosenberg SA, editors. Cancer principles and practice of oncology, 8th ed. Philadelphia, PA, USA: Lippincott-Raven; 2008:1741–94.
5. Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol. 2007;25:2755–63.
6. Borden EC, Amato DA, Rosenbaum C, et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol. 1987;5:840–50.
7. Palumbo R, Palmeri S, Antimi M, et al. Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas. Ann Oncol. 1997;8:1159–62.
8. Richon VM. Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor. Br J Cancer. 2006;95(Suppl 1):S2–6.
9. Mann BS, Johnson JR, Sridhara R, et al. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res. 2007;13:2318–22.
10. Kelly WK, O’Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol. 2005;23:3923–31.
11. Olsen EA, Kim Y-H, Kuzel TM, et al. Phase Ib multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25:3109–15.
12. Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109:31–9.
13. Garcia-Manero G, Yang H, Bueso-Ramos C, et al. Phase I study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced leukemias and myelodysplastic syndromes. Blood. 2008;111:1060–6.
14. O’Connor OA, Heaney ML, Schwartz L, et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol. 2006;24:166–73.
15. Richardson P, Mitsiades C, Colson K, et al. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma. 2008;49:502–7.
16. Crump M, Coiffier B, Jacobsen ED, et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol. 2008;19:964–9.
17. Badros A, Burger AM, Philip S, et al. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res 2009;15:5250–7.

18. Krug LM, Curley T, Schwartz L, et al. Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer 2006;7:257–61.

19. Blumenschein Jr, Kies MS, Papadimitrakopoulou VA, et al. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs 2008;26:81–7.

20. Luu TH, Morgan RJ, Leong L, et al. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California cancer consortium study. Clin Cancer Res 2008;14:7138–42.

21. Traynor AM, Dube S, Eickhoff JC, et al. Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin oncology network phase II study. J Thorac Oncol 2009;4:522–6.

22. Vansteenkiste J, Van CE, Dumetz H, et al. Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Invest New Drugs 2008;26:483–8.

23. Modesitt SC, Sill M, Hoffman JS, et al. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study. Gynecol Oncol 2008;109:182–6.

24. Duvic M, Olsen EA, Breneman D, et al. Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma (CTCL). Clin Lymphoma Myeloma (in press).

25. Skubitz KM, Skubitz AP. Differential gene expression in leiomyosarcoma. Cancer. 2003;98:1029–38.

26. Trzyna W, McHugh M, McCue P, et al. Molecular determination of the malignant potential of smooth muscle neoplasms. Cancer. 1997;80:211–7.

27. Miyajima K, Tamiya S, Oda Y, et al. Relative quantitation of p53 and MDM2 gene expression in leiomyosarcoma: real-time semi-quantitative reverse transcription-polymerase chain reaction. Cancer Lett. 2001;164:177–88.

28. Glaser KB. HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol. 2007;74:659–71.

29. Shahbazi MD, Grunstein M. Functions of site-specific histone acetylation and deacetylation. Annu Rev Biochem. 2007;76:75–100.

30. Martinez-Iglesias O, Ruiz-Llorente L, Sanchez-Martinez R, et al. Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer. Clin Transl Oncol. 2008;10:395–8.

31. Nguyen A, Su L, Campbell B, et al. Synergism of heat shock protein 90 and histone deacetylase inhibitors in synovial sarcoma. Sarcoma. 2009;794–901.

32. Ecke I, Petry F, Rosenberger A, et al. Antitumor effects of a combined 5-aza-2′-deoxycytidine and valproic acid treatment on rhabdomyosarcoma and medulloblastoma in Pcth mutant mice. Cancer Res 2009;69:887–95.

33. Hurtubise A, Bernstein ML, Momparler RL. Preclinical evaluation of the antineoplastic action of 5-aza-2′-deoxycytidine and different histone deacetylase inhibitors on human Ewing’s sarcoma cells. Cancer Cell Int. 2008;8:16.

34. Yamanoto S, Tanaka K, Sakimura R, et al. Suberoylanilide hydroxamic acid (SAHA) induces apoptosis or autophagy-associated cell death in chondrosarcoma cell lines. Anticancer Res 2008;28:1585–91.

35. Lubieniecka JM, de Bruijn DR, Su L, et al. Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma. Cancer Res 2008;68:4503–10.

36. Hrzenjak A, Kremsler ML, Strohmeier B, et al. SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway. J Pathol 2008;216:495–504.

37. Sakimura R, Tanaka K, Yamamoto S, et al. The effects of histone deacetylase inhibitors on the induction of differentiation in chondrosarcoma cells. Clin Cancer Res 2007;13:275–82.

38. Navid F, Mischen BT, Helman LJ. Low dose histone deacetylase inhibitor, depsipeptide (FR901228), promotes adenosine transduction in human rhabdomyosarcoma cell lines. Sarcoma. 2004;8:25–30.

39. Lopez G, Liu J, Ren W, et al. Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma. Clin Cancer Res 2009;15:3472–83.

Publish with Libertas Academica and every scientist working in your field can read your article

“I would like to say that this is the most author-friendly editing process I have experienced in over 150 publications. Thank you most sincerely.”

“The communication between your staff and me has been terrific. Whenever progress is made with the manuscript, I receive notice. Quite honestly, I’ve never had such complete communication with a journal.”

“LA is different, and hopefully represents a kind of scientific publication machinery that removes the hurdles from free flow of scientific thought.”

Your paper will be:
- Available to your entire community free of charge
- Fairly and quickly peer reviewed
- Yours! You retain copyright

http://www.la-press.com